Bayer AG
BAYRYDEBayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.
Enterprise value over trailing (LTM) vs. forward (NTM) fundamentals. Click an LTM cell to chart it.
- Sector
- Pharma & Biotech
- Sub-sector
- Large-Cap & Specialty Pharmaceuticals
- Listing
- BAYRY
- Country
- DE
Annual financials & analyst forecasts
| $M | CY2021 | CY2022 | CY2023 | CY2024 | CY2025 | CY2026E | CY2027E |
|---|---|---|---|---|---|---|---|
| Revenue YoY | — | 15% | -6% | -2% | -2% | 1% | 3% |
| Revenue | $44.08B | $50.74B | $47.64B | $46.61B | $45.47B | $45.78B | $46.93B |
| Gross Profit | $27.27B | $30.87B | $27.89B | $25.34B | $26.71B | — | — |
| Gross Profit Margin | 61.9% | 60.8% | 58.5% | 54.4% | 58.8% | — | — |
| EBITDA | $7.78B | $11.41B | $7.40B | $8.82B | $6.45B | $14.17B | $14.53B |
| EBITDA Margin | 17.6% | 22.5% | 15.5% | 18.9% | 14.2% | 31.0% | 31.0% |
| EBIT | $3.01B | $6.53B | $1.59B | $7.30B | $3.48B | $7.80B | $8.00B |
| Net Income | $1.00B | $4.16B | ($2.94B) | ($2.55B) | ($3.58B) | $4.31B | $4.56B |
| Free Cash Flow | $2.48B | $4.14B | $2.02B | $4.05B | $2.59B | — | — |
| FCF Margin | 5.6% | 8.2% | 4.2% | 8.7% | 5.7% | — | — |
| Short-Term Debt | $2.82B | $7.58B | $4.41B | $4.90B | $5.63B | — | — |
| Long-Term Debt | $35.55B | $32.83B | $37.23B | $34.55B | $30.77B | — | — |
| Cash & Cash Equivalents | $4.56B | $5.17B | $5.91B | $6.19B | $6.67B | — | — |
| Net Debt | $33.80B | $35.24B | $35.73B | $33.26B | $29.73B | — | — |
| Net Debt / EBITDA | 4.3x | 3.1x | 4.8x | 3.8x | 4.6x | — | — |
| Rule of 40 | — | 23.3% | -1.9% | 6.5% | 3.3% | — | — |